GXP RIZATRIPTAN rizatriptan (as benzoate) 10 mg orally disintegrating tablets blisters

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

rizatriptan benzoate, Quantity: 14.53 mg (Equivalent: rizatriptan, Qty 10 mg)

Disponible depuis:

Arrotex Pharmaceuticals Pty Ltd

DCI (Dénomination commune internationale):

rizatriptan benzoate

forme pharmaceutique:

Tablet, orally disintegrating

Composition:

Excipient Ingredients: acesulfame potassium; crospovidone; ethylcellulose; hypromellose; sodium stearylfumarate; silicon dioxide; mannitol; colloidal anhydrous silica; Flavour

Mode d'administration:

Sublingual

Unités en paquet:

3, 1, 6, 2

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

for acute treatment of migraine attacks with or without aura.

Descriptif du produit:

Visual Identification: White to off-white, round, flat face beveled edge tablets, debossed with 'C7' on one side and 'C' on the other side, having a characteristic flavour.; Container Type: Blister Pack; Container Material: Other composite material; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Statut de autorisation:

Licence status A

Date de l'autorisation:

2015-03-20